C WorldWide Group Holding A S Purchases 50,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

C WorldWide Group Holding A S boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 19.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 303,851 shares of the biotechnology company's stock after acquiring an additional 50,000 shares during the quarter. BioMarin Pharmaceutical accounts for 0.4% of C WorldWide Group Holding A S's holdings, making the stock its 26th largest holding. C WorldWide Group Holding A S owned 0.16% of BioMarin Pharmaceutical worth $29,297,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. Barclays PLC boosted its position in BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company's stock valued at $493,111,000 after buying an additional 1,336,886 shares in the last quarter. Ameriprise Financial Inc. boosted its position in BioMarin Pharmaceutical by 5.6% in the third quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company's stock valued at $456,906,000 after buying an additional 275,436 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in BioMarin Pharmaceutical by 10.7% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,308,245 shares of the biotechnology company's stock valued at $115,754,000 after buying an additional 126,680 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in BioMarin Pharmaceutical by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,304,797 shares of the biotechnology company's stock valued at $115,448,000 after buying an additional 33,592 shares in the last quarter. Finally, Northern Trust Corp boosted its position in BioMarin Pharmaceutical by 3.7% in the third quarter. Northern Trust Corp now owns 1,219,814 shares of the biotechnology company's stock valued at $107,929,000 after buying an additional 43,695 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMRN. Morgan Stanley cut their price target on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an "overweight" rating on the stock in a report on Friday. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Wells Fargo & Company lifted their price target on shares of BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Thursday. Scotiabank lifted their price target on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a "sector perform" rating in a research note on Thursday. Finally, Canaccord Genuity Group decreased their price target on shares of BioMarin Pharmaceutical from $91.00 to $89.00 and set a "hold" rating for the company in a research note on Friday. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $107.50.

BioMarin Pharmaceutical Stock Down 1.5 %

BMRN stock traded down $1.26 during trading on Friday, reaching $80.91. The stock had a trading volume of 2,257,132 shares, compared to its average volume of 1,697,110. BioMarin Pharmaceutical Inc. has a one year low of $76.02 and a one year high of $99.56. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12. The company's 50 day moving average is $87.58 and its two-hundred day moving average is $89.14. The company has a market capitalization of $15.27 billion, a price-to-earnings ratio of 75.62, a P/E/G ratio of 1.51 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. The business had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.39%. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.11 EPS. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 1.85 EPS for the current year.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, Director Jean Jacques Bienaime sold 20,000 shares of the company's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Jean Jacques Bienaime sold 20,000 shares of the company's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $91.26, for a total transaction of $1,825,200.00. Following the sale, the director now directly owns 474,994 shares in the company, valued at approximately $43,347,952.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Henry J. Fuchs sold 35,341 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares in the company, valued at $18,068,126.06. The disclosure for this sale can be found here. Insiders have sold a total of 103,229 shares of company stock worth $9,062,967 over the last three months. 1.84% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.